13/ Thus, while developing treatments for rare diseases is actually significantly cheaper than non-rare diseases, the current model has created a gap in funding. https://t.co/k0k5h7n3uj
Regulatory bodies make it unlikely that companies will risk their capital to save your life if you have a rare disease. "Orphan" drugs have an expedited process, but the average cost is still $166M vs $291M, so drug market size still weighs heavily. https
#RT @aHUSAllianceAct: Interesting article w/ #RareDiseaseDay approaching 28 Feb 2021 - "We found that the out-of-pocket clinical costs per approved #orphandrug to be $166 million and $291 million (2013 USD) per non-orphan #drug." #clinicaltrial #pharma htt
RT @aHUSAllianceAct: Interesting article w/ #RareDiseaseDay approaching 28 Feb 2021 - "We found that the out-of-pocket clinical costs per a…
Interesting article w/ #RareDiseaseDay approaching 28 Feb 2021 - "We found that the out-of-pocket clinical costs per approved #orphandrug to be $166 million and $291 million (2013 USD) per non-orphan #drug." #clinicaltrial #pharma https://t.co/IPdGyiz08V
One of our most popular and important articles from the last year, taking a look at the clinical cost of drug development for #orphandrugs versus non-orphan drugs #RareDiseaseDay https://t.co/TA4400fnyf https://t.co/pdNnViNl1L
A hard analysis to do, but an interesting and thoughtful article on #drugdiscovery and development costs of #pharmaceuticals #biotech #RareDisease #clinicaltrials #economics @UofTPharmacy https://t.co/oVfC1GGDKm
An interesting paper suggestion from Cassiman on this issue. @aidanhollis who presented also at day 1 #IBRD19 is a co-author on this study. https://t.co/7iJXkIbh45 https://t.co/jckSIfA8qo
RT @cpontesg: Estimating the clinical cost of drug development for orphan versus non-orphan drugs: development or orphans is quite less cos…
RT @cpontesg: Estimating the clinical cost of drug development for orphan versus non-orphan drugs: development or orphans is quite less cos…
RT @cpontesg: Estimating the clinical cost of drug development for orphan versus non-orphan drugs: development or orphans is quite less cos…
RT @cpontesg: Estimating the clinical cost of drug development for orphan versus non-orphan drugs: development or orphans is quite less cos…
Estimating the clinical cost of drug development for orphan versus non-orphan drugs: development or orphans is quite less costly. Time to revisit pricing? https://t.co/gLFIzCmc97
The capitalized clinical costs per approved orphan drug and non-orphandrug were estimated to be $291 million and $412 million respectively. For new molecular entities, capitalized clinical cost per approved orphan drug was half that of a non-orphan drug ht
#orphandrugs are often $$$$, often blamed on cost of development, but how much do we know about how to estimate that cost? Research from @j_hoch in our #HealthPolicy and Management Division looks at this problem https://t.co/G8HSyt9ni1 #RareDisease #hea
Estimating the clinical cost of drug development for orphan versus non-orphan drugs https://t.co/vmf7Fs2Bc5
Research by @j_hoch from @UCDavis_HPM @UCDavis_PHS @UCDavis estimates the differences in trial characteristics and clinical development costs between 100 orphan and 100 non-orphan drugs. See https://t.co/ABWjAidw7J @UCDavisGrad @UCDavisHealth @UCDavisRes
RT @PabloRichly: Desarrollar un medicamento para una nueva indicación podría costar la mitad que para una indicación con un tratamiento apr…
RT @pulseinfoframe: An interesting discussion on the rising costs of developing orphan drugs. #rarediseases https://t.co/LyVJjyYhqn
Desarrollar un medicamento para una nueva indicación podría costar la mitad que para una indicación con un tratamiento aprobado. Su precio desorbitante no sería por el costo de desarrollo sino un plan de negocios. https://t.co/o7Ym5NfXjN
An interesting discussion on the rising costs of developing orphan drugs. #rarediseases https://t.co/LyVJjyYhqn
Estimating the clinical cost of drug development for orphan versus non-orphan drugs https://t.co/iAoOUtoEag
RT @ellenthoen: Yes, and so should the incentives mechanisms.@YNatsis @HAImedicines https://t.co/FdU76A3Xe8
Yes, and so should the incentives mechanisms.@YNatsis @HAImedicines
RT @aidanhollis: New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on averag…
RT @aidanhollis: New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on averag…
RT @aidanhollis: New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on averag…
What a very interesting and a very important paper. Thanks for sharing @SteveUBC
RT @SteveUBC: Estimated cost of orphan drug trials are dramatically less than industry talking-points. Prices should, indeed, reflect this.…
RT @aidanhollis: New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on averag…
RT @aidanhollis: New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on averag…
RT @aidanhollis: New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on averag…
RT @aidanhollis: New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on averag…
RT @aidanhollis: New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on averag…
RT @aidanhollis: New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on averag…
RT @aidanhollis: New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on averag…
New study on orphan drug development costs: orphan drug clinical costs are about half those of non-orphan drugs, on average. Publicly sourced data. Should prices reflect this? https://t.co/EpcLDGgDZv @jamie_love @eurordis @RareDiseases @raredisorders @RoKh